Drug delivery company IntelGenx (CVE:IGX) missed expectations on Wall Street yesterday with its second quarter results.
The Quebec-based company posted a net loss of -$550,000 on sales of $1.1 million for the 3 months ended June 30, paring its losses by 32% on sales growth of 64% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.